The chief research officer of the Muscular Dystrophy Association spoke on the FDA's approval of a high-dose regimen of nusinersen and how it fits into an increasingly complex treatment landscape. [WATCH TIME: 11 minutes]
Angela Lek, PhD
Advertisement
Vice President of Research, Muscular Dystrophy Association
Articles by Angela Lek, PhD
The chief research officer of the Muscular Dystrophy Association spoke on highlights and themes from the organization's 2026 Clinical and Scientific Conference. [WATCH TIME: 9 minutes]
Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, provided an outlook on the 2026 MDA meeting and what clinicians should look forward to in preparation.
The chief research officer of the Muscular Dystrophy Association outlined MDA’s growing focus on muscle regeneration research and explains why the 2026 MDA Conference is a must-attend meeting for clinicians. [WATCH TIME: 3 minutes]
The chief research officer of the Muscular Dystrophy Association outlined emerging scientific priorities and community-driven initiatives shaping the 2026 MDA Clinical and Scientific Conference. [WATCH TIME: 4 minutes]
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Efgartigimod Shows Non-Inferior Disability Improvement and Greater Muscle Strength Recovery Versus Plasma Exchange in Real-World GBS Study
2
The Promise and Limitations of Neurofilament Light Chain in Peripheral Nerve Disorders: Brett Morrison, MD, PhD
3
IVIg and Plasma Exchange Show Comparable Functional Outcomes in Guillain-Barre Syndrome
4
Riliprubart Shows Sustained Improvements in Fatigue, Pain, and Quality of Life in Phase 2 CIDP Study
5